Stéphanie Lheureux, MD, PhD

Dr. Lheureux obtained her MD in Medical Oncology and PhD in translational research from France and moved to Toronto for a Clinical Research Fellowship to focus on Gynecological Cancers and Drug Development. She is Site Lead, Gynecologic Oncology and Clinician Investigator at Princess Margaret Cancer Centre (PM) and holds an Assistant Professor position in the Faculty of Medicine, at the University of Toronto. She serves as co-Chair of the NCI Cervical Task Force on Clinical Trials and have served as a member of the Steering Committee on Uterine Cancers. She is Principal Investigator of several international studies and involved in the development of early phase clinical trials with an emphasis on drug development and translational research in gynecologic malignancies.

Her academic interest is the design and development of early phase clinical trials of targeted agents in gynecologic cancers that incorporate translational endpoints and quality of life measures. This includes but is not limited to examination of chemoprevention approaches, targeted or precision therapies, immune-oncology agents, as well as leading improvements in quality of advanced cancer care. Academically, these interests have included interrogating extreme outliers of response and resistance across the disease continuum as a means of identifying predictors of therapeutic response. In particular, deep analysis of BRCA1/2 mutations in gynecologic cancers of high grade serous histology. In the last five years, she has >40 peer-reviewed publications in widely cited journals such as CA: Cancer Journal for Clinicians (IF=244), Clinical Cancer Research, JAMA Oncology, Journal of Clinical Oncology, Lancet Oncology and Gynecology Oncology. She is PI or co-PI in several large-scale peer reviewed funding opportunities from the Canadian Cancer Society Research Institute, Ontario Institute for Cancer Research and Terry Fox Research Institute that converge preclinical and clinical areas of interest and benefit from her unique expertise in each of these domains. 

Dr. Lheureux's clinical and research interests are on integrating translational research in early phase gynecologic cancer clinical trials and incorporating these findings into the clinic in a timely manner. She is a principal investigator or sub-investigator for numerous clinical trials in gynecologic cancers at Princess Margaret, a member of the Gynecologic Cancer InterGroup, and co-investigator on several large scale programs supported by the Canadian Cancer Society Research Institute and the Ontario Institute for Cancer Research.

J Clin Oncol. 2019 Aug 12;:JCO1900347
Lheureux S, Mirza M, Coleman R
Clin Cancer Res. 2019 Jul 23;:
Ishak CA, Lheureux S, De Carvalho DD
Eur Urol Oncol. 2019 Jul 19;:
Bersanelli M, Iacovelli R, Buti S, Houede N, Laguerre B, Procopio G, Lheureux S, Fischer R, Negrier S, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C
CA Cancer J Clin. 2019 Jul;69(4):280-304
Lheureux S, Braunstein M, Oza AM
Nat Rev Cancer. 2019 06;19(6):339-348
Saner FAM, Herschtal A, Nelson BH, deFazio A, Goode EL, Ramus SJ, Pandey A, Beach JA, Fereday S, Berchuck A, Lheureux S, Pearce CL, Pharoah PD, Pike MC, Garsed DW, Bowtell DDL
Lancet. 2019 Mar 23;393(10177):1240-1253
Lheureux S, Gourley C, Vergote I, Oza AM
Cancers (Basel). 2019 Mar 23;11(3):
Madariaga A, Lheureux S, Oza AM
J Immunother Cancer. 2019 Mar 13;7(1):72
Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S,...
Gynecol Oncol. 2019 Feb 18;:
Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM